Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY Bristol-Myers Squibb Company daily Stock Chart
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E19.67 EPS (ttm)2.67 Insider Own0.16% Shs Outstand1.63B Perf Week2.41%
Market Cap85.83B Forward P/E13.09 EPS next Y4.02 Insider Trans0.00% Shs Float1.63B Perf Month-8.71%
Income4.38B PEG1.79 EPS next Q0.83 Inst Own74.40% Short Float0.70% Perf Quarter-12.73%
Sales22.04B P/S3.89 EPS this Y-10.90% Inst Trans0.08% Short Ratio1.58 Perf Half Y0.73%
Book/sh8.36 P/B6.29 EPS next Y4.01% ROA4.30% Target Price59.47 Perf Year-13.77%
Cash/sh4.19 P/C12.57 EPS next 5Y10.98% ROE11.30% 52W Range46.94 - 70.05 Perf YTD-14.18%
Dividend1.60 P/FCF77.04 EPS past 5Y15.30% ROI20.20% 52W High-24.93% Beta1.11
Dividend %3.04% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin70.80% 52W Low12.04% ATR1.62
Employees23700 Current Ratio1.50 Sales Q/Q8.30% Oper. Margin24.40% RSI (14)44.08 Volatility1.97% 3.02%
OptionableYes Debt/Eq0.54 EPS Q/Q128.60% Profit Margin6.50% Rel Volume0.60 Prev Close52.85
ShortableYes LT Debt/Eq0.42 EarningsOct 25 BMO Payout180.60% Avg Volume7.20M Price52.59
Recom2.50 SMA200.60% SMA50-8.73% SMA200-9.72% Volume4,338,605 Change-0.49%
Oct-22-18Downgrade Citigroup Buy → Neutral
Oct-09-18Resumed Guggenheim Neutral
Aug-08-18Upgrade Atlantic Equities Underweight → Neutral
Apr-17-18Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-12-18Reiterated Citigroup Buy $78 → $70
Mar-20-18Reiterated JP Morgan Overweight $70 → $75
Feb-15-18Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-30-17Upgrade SunTrust Hold → Buy
Oct-16-17Downgrade Jefferies Buy → Hold
Sep-12-17Downgrade Hilliard Lyons Long-term Buy → Neutral
Dec-19-16Upgrade Jefferies Hold → Buy
Oct-28-16Reiterated Deutsche Bank Hold $59 → $52
Sep-09-16Reiterated Barclays Equal Weight $75 → $65
Aug-11-16Downgrade Berenberg Buy → Hold
Aug-08-16Reiterated Deutsche Bank Hold $68 → $62
Aug-08-16Downgrade Credit Suisse Outperform → Neutral $63
Aug-05-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-23-16Initiated Hilliard Lyons Neutral
Apr-29-16Reiterated UBS Buy $73 → $80
Apr-29-16Reiterated Barclays Equal Weight $70 → $75
Nov-13-18 01:17PM  Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates Zacks
07:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Bristol-Myers Squibb ACCESSWIRE
Nov-12-18 04:23PM  Nektar Bounds Higher On 'Promising Contender' In Cancer Immunotherapy Investor's Business Daily
07:05AM  Today's Research Reports on Trending Tickers: Heron Therapeutics and Bristol-Myers Squibb ACCESSWIRE
Nov-11-18 08:13PM  How Bristol-Myers Squibb Company Fell $18.8 Billion in October Motley Fool
Nov-09-18 03:17PM  Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update Zacks
02:23PM  Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag Zacks
01:25PM  Highly Rated 'Surgeon' For Biologic-Drug Makers Soars 85% In 2018 Investor's Business Daily
08:56AM  The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp Zacks
07:31AM  Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug Zacks
07:00AM  Today's Research Reports on Trending Tickers: AstraZeneca and Bristol-Myers Squibb ACCESSWIRE
Nov-08-18 05:45PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
01:42PM  Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit - sources Reuters
01:39PM  Stada, Angelini among final bidders for $1 bln Bristol-Myers' UPSA unit - sources Reuters
01:14PM  Stada, Angelini among final bidders for $1 bln Bristol-Myers' Upsa unit - sources Reuters
11:36AM  Edited Transcript of BMY earnings conference call or presentation 25-Oct-18 2:30pm GMT Thomson Reuters StreetEvents
11:13AM  Horizon Pharma (HZNP) Q3 Earnings & Sales Beat, Shares Rise Zacks
11:07AM  Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q3 Zacks
09:39AM  Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss Zacks
08:14AM  Democrats Hold Edge in House Battle: 5 Great Picks (Revised) Zacks
08:09AM  Wall Street Likely to Sustain Post-Midterm Rally: 5 Picks Zacks
Nov-07-18 04:08PM  Mallinckrodt (MNK) Beats on Q3 Earnings Estimates, Ups View Zacks
10:50AM  Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer Zacks
09:23AM  Why Nektar Therapeutics Fell 36.5% in October Motley Fool
07:50AM  The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie Benzinga
06:59AM  Bristol-Myers Squibb to Take Part in Credit Suisse 2018 Health Care Conference Business Wire
Nov-06-18 04:34PM  U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma Business Wire
04:31PM  Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3 Zacks
04:30PM  Why Nektar Therapeutics Tumbled 10% Today Motley Fool
11:20AM  Beaten-Down Pharma ETFs to Buy Post Q3 Results Zacks
09:30AM  BMY vs. AZN: Which Stock Is the Better Value Option? Zacks
07:00AM  Democrats Hold Edge in House Battle: 5 Great Picks Zacks
Nov-05-18 02:25PM  Corcept (CORT) Q3 Earnings In Line, Revenues Miss Estimates Zacks
02:20PM  Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q3 Zacks
07:49AM  The Zacks Analyst Blog Highlights: Newfield Exploration, Amazon.com, Bristol-Myers Squibb, Eaton and CF Industries Holdings Zacks
06:59AM  Bristol-Myers Squibb and Infinity Pharmaceuticals Announce a New Clinical Collaboration to Evaluate Opdivo (Nivolumab) in Combination with IPI-549 in Urothelial Cancer PR Newswire
Nov-02-18 06:11PM  AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues Zacks
Nov-01-18 05:13PM  Bristol-Myers Squibb plans layoffs of ZymoGenetics' remaining Seattle-area employees American City Business Journals
04:56PM  Novo Nordisk (NVO) Reports In-Line Q3 Earnings, Beats Sales Zacks
04:50PM  Zoetis (ZTS) Beats on Q3 Earnings & Sales, Updates '18 View Zacks
Oct-31-18 02:52PM  The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead Zacks
08:17AM  Zacks.com highlights: Bristol-Myers Squibb, United Rentals, Capital One Financial and Harris Zacks
08:01AM  The Zacks Analyst Blog Highlights: ArcBest, Express, Arch Coal, Bristol-Myers Squibb and Methanex Zacks
Oct-30-18 10:28AM  Is Halloween the Best Time to Invest? 5 Solid Buys Zacks
Oct-29-18 07:27PM  Bristol-Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know Zacks
05:48AM  The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers (Revised) Zacks
Oct-26-18 11:39AM  Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO Zacks
Oct-25-18 06:55PM  Bristol-Myers Squibb Co (BMY) Q3 2018 Earnings Conference Call Transcript Motley Fool
02:25PM  Pharma Giants Merck, Bristol Diverge On Earnings Beat As Sales Lag Investor's Business Daily
11:44AM  Merck and Bristol-Myers Squibb Are Seeing Rising Sales of Their Cancer Drugs Barrons.com
11:37AM  Bristol-Myers (BMY) Beats on Q3 Earnings, Raises EPS View Zacks
10:43AM  Merck, Bristol-Myers profits rise on cancer drug sales Reuters
09:34AM  Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales TheStreet.com
09:15AM  Why Bristol-Myers Squibb (BMY) is a Top Dividend Stock for Your Portfolio Zacks
08:30AM  A Spotlight On Bristol-Myers Squibb Companys (NYSE:BMY) Fundamentals Simply Wall St.
08:25AM  Bristol-Myers Squibb (BMY) Q3 Earnings Beat Estimates Zacks
08:00AM  Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology PR Newswire
07:38AM  Bristol-Myers: 3Q Earnings Snapshot Associated Press
07:18AM  Bristol-Myers stock rises 2.4% after Q3 profit beat, upbeat 2018 guidance MarketWatch
07:01AM  [$$] Bristol-Myers Squibb Raises Full-Year Profit Forecast The Wall Street Journal
06:59AM  Bristol-Myers profit rises on better-than-expected cancer drug sales Reuters
06:59AM  Bristol-Myers Squibb Reports Third Quarter Financial Results Business Wire
Oct-24-18 02:45PM  Bristol-Myers Squibb Q3 Earnings Outlook Benzinga
09:33AM  Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG Zacks
Oct-23-18 11:04AM  Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC Zacks
07:36AM  The Zacks Analyst Blog Highlights: Roche, Gilead and Bristol Myers Zacks
Oct-22-18 07:54PM  [$$] Bristol-Myers Faces a Costly Delay The Wall Street Journal -6.30%
05:48PM  Why Nektar Therapeutics Crashed 17.2% Today Motley Fool
04:49PM  Mirati Shares Fall After Cancer Trial Progress Report TheStreet.com
04:45PM  Biotech Dives After Lung Cancer Regimen With Bristol Disappoints Investor's Business Daily
04:25PM  MarketPulse: Healthcare Slips as Bristol-Myers Squibb Sinks Investing.com
04:20PM  Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy TheStreet.com
04:03PM  Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises TheStreet.com
01:47PM  Will Bristol-Myers move higher? Is Activision Blizzard ov... CNBC Videos
01:03PM  [$$] Bristol-Myers Faces a Costly Delay The Wall Street Journal
11:51AM  Why Mirati Therapeutics Inc. Is Plunging Today Motley Fool
10:37AM  Mirati Therapeutics stock drops 19.5% after cancer trial results MarketWatch
10:36AM  Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug MarketWatch
08:35AM  Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings? Zacks
07:10AM  Are Bristol-Myers Squibb Companys (NYSE:BMY) Interest Costs Too High? Simply Wall St.
06:45AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Business Wire
03:20AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma Business Wire
03:15AM  Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Durable Clinical Benefit in Previously Untreated Patients with MSI-H or dMMR Metastatic Colorectal Cancer Business Wire
Oct-20-18 03:15AM  Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Shows Promising Results in Patients with Advanced Form of Bladder Cancer Business Wire
Oct-19-18 04:16PM  Bristol-Myers Squibb Provides Update on the Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Patients with Tumor Mutational Burden 10 mut/Mb Business Wire
09:30AM  BMY vs. LLY: Which Stock Should Value Investors Buy Now? Zacks
08:00AM  Today's Research Reports on Trending Tickers: Merck & Co., and Bristol-Myers Squibb ACCESSWIRE
Oct-17-18 06:59AM  Bristol-Myers Squibb to Showcase Immunoscience Research and Biomarker-Guided Treatment Approaches at the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting Business Wire
Oct-16-18 01:23PM  Government wants drug companies to disclose prices on TV ads Yahoo Finance Video
Oct-15-18 05:06PM  Health Care Digest: Big IPO seeks big space, East Bay genomics company hires CFO, biotech award winners American City Business Journals
08:52AM  Bristol-Myers Reports Disappointing Data From SCLC Study Zacks
08:37AM  Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International Zacks
Oct-12-18 10:25AM  Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal Zacks
09:30AM  Bristol-Myers Inks Deal and Invests $12 Million in Compugen Zacks
09:28AM  4 Top Stocks to Buy for Superb Earnings Growth Zacks
07:33AM  Bristol-Myers' Opdivo fails to meet lung cancer study goal Reuters
07:14AM  Bristol-Myers' Opdivo fails to meet lung cancer study goal Reuters
07:04AM  Bristol-Myers says trial of small cell lung cancer treatment failed to meet main goal MarketWatch
06:59AM  Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer Business Wire
Oct-11-18 07:32AM  Compugen's stock shoots up after Bristol-Myers to pay 52% premium for equity stake MarketWatch -5.38%
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; and Compugen Ltd.; and Tsinghua University, as well as a research partnership with Sirenas. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Biondi PaulSVP, Head of Strategy & BDOct 02Option Exercise0.005920592Oct 04 04:56 PM
Dubow AdamChief Compliance & Ethics OffiSep 03Option Exercise0.00797015,495Sep 05 04:49 PM
Santiago Karen MurphyControllerSep 01Option Exercise0.0064104,057Sep 05 04:49 PM
Gordon MurdoEVP, Chief Commercial OfficerAug 01Option Exercise0.001,510050,168Aug 03 05:05 PM
Biondi PaulSVP, Head of Strategy & BDJul 01Option Exercise0.001,46101,461Jul 03 09:24 PM
Caforio GiovanniChairman and CEOMay 05Option Exercise0.008,0400292,822May 08 05:05 PM
Paliwal Dinesh CDirectorApr 30Buy52.404,770249,9488,027May 02 04:05 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerApr 03Option Exercise0.0012,367018,267Apr 05 04:37 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00219,2110333,970Mar 13 04:56 PM
JUDGE ANN POWELLSVP, Global Human ResourcesMar 10Option Exercise0.0036,044075,370Mar 13 04:56 PM
Elicker John ESVP, Public Affairs & IRMar 10Option Exercise0.0020,043086,932Mar 13 04:56 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.0034,681053,132Mar 13 04:57 PM
Gordon MurdoEVP, Chief Commercial OfficerMar 10Option Exercise0.0039,235062,028Mar 13 04:55 PM
Santiago Karen MurphyControllerMar 10Option Exercise0.004,40704,456Mar 13 04:55 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.0091,3180363,739Mar 13 04:53 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.0031,2750136,441Mar 13 04:54 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0068,8960488,677Mar 13 04:54 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 23Option Exercise22.1437,460829,364302,348Feb 27 04:45 PM
Samuels Theodore R. IIDirectorDec 15Buy62.304,000249,18722,000Dec 18 04:21 PM
Lynch Thomas J. Jr.EVP & Chief Scientific OfficerDec 12Sale63.245,300335,1729,251Dec 13 05:31 PM
LEUNG SANDRAEVP, General CounselDec 04Option Exercise22.14156,5823,466,725584,373Dec 05 06:15 PM
LEUNG SANDRAEVP, General CounselDec 04Sale63.37156,5829,922,601427,791Dec 05 06:15 PM
Bancroft Charles AEVP & Chief Financial OfficerDec 02Option Exercise0.006,4010267,770Dec 05 06:15 PM